Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Stopped early · Phase 2

Conditions studied: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)

In brief

This study is designed to evaluate the efficacy of pamiparib in participants with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency (CTC-HRD). All participants will receive pamiparib. The purpose of this study is to demonstrate that pamiparib will improve Objective Response Rate (ORR) and Prostate-Specific Antigen (PSA) response rate

Key facts

Study ID

NCT03712930

Run by

BeiGene

People needed

13

Starts

2019-02-05

Expected to finish

2020-09-02

Last updated by the study team

2021-11-17

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• University Cancer and Blood Center — Athens, Georgia, United States
• Montefiore Einstein Cancer Center — The Bronx, New York, United States
• University of Washington — Seattle, Washington, United States
• Gosford Hospital — Gosford, New South Wales, Australia
• Liverpool Hospital — Liverpool, New South Wales, Australia
• Calvary Mater Newcastle — Waratah, New South Wales, Australia
• Icon Cancer Care Foundation — South Brisbane, Queensland, Australia
• Pan American Oncology Trials, LLC — Rio Piedras, Puerto Rico
• L Hospitalet de Llobregat — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.